SCHEMBL4463980

SCHEMBL4463980

COC1=CC(=O)C(Cl)=C(OC)C1=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HKDC1 Q2TB90 2/20 0.67
IDO1 P14902 1/20 0.50
CDC25A P30304 1/20 0.50
CDC25B P30305 1/20 0.50
KDM4E B2RXH2 2/20 0.46
MAPT P10636 2/20 0.46
MAPK1 P28482 2/20 0.46
MEN1 O00255 1/20 0.46
USP2 O75604 1/20 0.46
TP53 P04637 1/20 0.46
CYP3A4 P08684 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ALOX5 P09917 14/20 0.46
PTPN1 P18031 1/20 0.46
TDP2 O95551 1/20 0.45
NSD2 O96028 1/20 0.45
MPEG1 Q2M385 4/20 0.44
S1PR4 O95977 1/20 0.41
HSP90AA1 P07900 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9654553 0.83 HKDC1 (0.67) HKDC1IDO1CDC25ACDC25BKDM4E
SCHEMBL3413590 0.80 HKDC1 (1.00) HKDC1IDO1CDC25ACDC25BKDM4E
SCHEMBL31189916 0.79 HKDC1 (0.50) HKDC1IDO1CDC25ACDC25BKDM4E
SCHEMBL5163654 0.77 HKDC1 (0.69) HKDC1IDO1CDC25ACDC25BKDM4E
SCHEMBL5983372 0.74 HKDC1 (0.72) HKDC1IDO1CDC25ACDC25BKDM4E
SCHEMBL23201029 0.72 HKDC1 (0.62) HKDC1IDO1CDC25ACDC25BKDM4E
SCHEMBL9655259 0.72 ALOX5 (0.55) ALOX5MPEG1
SCHEMBL9578874 0.71 ALOX5 (0.70) ALOX5MPEG1
SCHEMBL4908282 0.71 MAPT (0.48) HKDC1IDO1CDC25ACDC25BKDM4E
SCHEMBL9578682 0.69 ALOX5 (0.77) HKDC1ALOX5MPEG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131705-A1 Practical, Cost-Effective Synthesis of Ubiquinones ZYMES, LLC 2009-05-21 US disclosed
EP-1968608-A2 PRACTICAL, COST-EFFECTIVE SYNTHESIS OF UBIQUINONES Zymes, LLC (US) 2008-09-17 EP disclosed
US-20070260076-A1 Practical, Cost-Effective Synthesis of Ubiquinones ZYMES, LLC 2007-11-08 US disclosed
WO-2007078679-A2 PRACTICAL, COST-EFFECTIVE SYNTHESIS OF UBIQUINONES ZYMES, LLC (US) 2007-07-12 WO disclosed
EP-1694623-A4 PRACTICAL, COST-EFFECTIVE SYNTHESIS OF UBIQUINONES ZYMES INC (US) 2007-01-17 EP disclosed
EP-1694623-A2 PRACTICAL, COST-EFFECTIVE SYNTHESIS OF UBIQUINONES Zymes, Inc. (US) 2006-08-30 EP disclosed
US-20060167289-A1 Practical, cost-effective synthesis of ubiquinones ZYMES, LLC (US) 2006-07-27 US disclosed
US-20050148675-A1 Practical, cost-effective synthesis of ubiquinones ZYMES, INC. (US) 2005-07-07 US disclosed
WO-2005056812-A2 PRACTICAL, COST-EFFECTIVE SYNTHESIS OF UBIQUINONES ZYMES, INC. (US) 2005-06-23 WO disclosed
EP-0355492-B1 REACTIVE DYES BAYER AG (DE) 1992-12-09 EP disclosed
EP-0141996-B1 TRIPHENDIOXAZINE REACTIVE DYES BAYER AG (DE) 1987-11-25 EP disclosed
EP-0229339-A2 Water soluble triphene dioxazine compounds, their starting compounds containing sulphonyl groups, process for their preparation and use of the triphene dioxazines as dyestuffs HOECHST AKTIENGESELLSCHAFT (DE) 1987-07-22 EP disclosed
EP-0144580-B1 TRIPHENDIOXAZINE DYES BAYER AG (DE) 1987-07-08 EP disclosed
EP-0222098-A2 Water soluble triphenodioxazine compounds, process for their preparation and their use as dyestuffs HOECHST AKTIENGESELLSCHAFT (DE) 1987-05-20 EP disclosed
US-4629788-A COLORFASTNESS; BLUE COLOR; NATURAL AND SYNTHETIC FIBER BAYER AKTIENGESELLSCHAFT (DE) 1986-12-16 US disclosed
US-4621138-A Triphendioxazine dyestuffs BAYER AKTIENGESELLSCHAFT (DE) 1986-11-04 US disclosed
US-4591643-A Triphendioxazine reactive dyestuffs BAYER AKTIENGESELLSCHAFT (DE) 1986-05-27 US disclosed
EP-0158882-A2 Triphenedioxazine dyes BAYER AG (DE) 1985-10-23 EP disclosed
EP-0144580-A2 Triphendioxazine dyes BAYER AG (DE) 1985-06-19 EP disclosed
EP-0141996-A2 Triphendioxazine reactive dyes BAYER AG (DE) 1985-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167289-A1 Practical, cost-effective synthesis of ubiquinones SQOR, NDUFS6, NDUFS5 HKDC1 1395/4885IDO1 1816/4885CDC25A 3959/4885
US-20070260076-A1 Practical, Cost-Effective Synthesis of Ubiquinones SQOR, NDUFS6, NDUFS5 HKDC1 1395/4885IDO1 1816/4885CDC25A 3959/4885
US-20090131705-A1 Practical, Cost-Effective Synthesis of Ubiquinones SQOR, NDUFS6, NDUFS5 HKDC1 1395/4885IDO1 1816/4885CDC25A 3959/4885
US-20050148675-A1 Practical, cost-effective synthesis of ubiquinones SQOR, NDUFS6, NDUFS5 HKDC1 1395/4885IDO1 1816/4885CDC25A 3959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.